[Variational trend in disease characteristics of hepatitis B-related primary liver cancer populations in the past five years: a retrospective single-center cross-sectional study].

Abstract

Objective: To study the variational trend in disease characteristics of patients with hepatitis B-related primary liver cancer (HBV-HCC) in the past five years. Method: A single-center retrospective cross-sectional analysis was performed to compare patients diagnosed with HBV-HCC from January 2012 to December 2016 (control group) and from January 2017 to December 2021 (observation group). The data of the study variables were extracted from the electronic medical record system of the hospital information system of the Second Hospital of Lanzhou University. The 1:2 propensity score matching was used to adjust potential confounding factors such as gender and age. Multivariate logistic regression analysis was used to study the factors affecting changes in disease characteristics of the HBV-HCC population in the observation group. GraphPad Prism 8.0 software was used to draw forest plots to intuitively display the effect size of the study variables in the logistic regression analysis.The t-test was used to compare normally distributed data between groups. The χ² test was used for inter-group comparison. Results: A total of 1 717 eligible cases were collected, including 510 in the control group and 1 207 in the observation group. Compared with the control group, the number of newly diagnosed cases in the observation group increased by 2.36 times, and males were still the main onset population (83.3% vs. 82.7%). The median age of onset increased (51.9 vs. 53.5 years, P<0.001). 79.4% of HBV-HCC patients had not received antiviral therapy, and the proportion of HBeAg-negative patients increased (56.4%). The factors affecting HBV-HCC patients included family history of HBV (OR=1.626, 95%CI: 1.181-2.238), family history of hepatocellular carcinoma (OR=1.388, 95%CI: 1.013-1.901), hypoviremia (OR=1.322, 95%CI: 1.046-1.671), abnormal alanine aminotransferase (OR=1.545, 95%CI: 1.231-1.940), liver fibrosis (OR=1.478, 95%CI: 1.153-1.894), liver cirrhosis (OR=1.431, 95%CI: 1.128-1.815), and metabolic-related fatty liver disease (OR=1.438, 95%CI: 1.116-1.815) after propensity score matching adjustment. The factors affecting HBeAg-positive patients were decreased (OR=0.390, 95%CI: 0.389-0.617); however, the number of early HBV-HCC diagnoses was increased (12.7% vs. 19.3%, P=0.001). Conclusion: The characteristics of patient disease and occurrence of HBV-HCC are changing over the past five years. The risk of developing hepatocellular carcinoma in middle- to older male patients with chronic hepatitis B is increasing with familial history of HBV and hepatocellular carcinoma, HBeAg negativity, hypoviremia, abnormal alanine aminotransferase, liver fibrosis, cirrhosis, and metabolic-related fatty liver disease.